Shionogi agrees $2 billion upfront purchase of IntraBio, adding oral rare-disease drug Aqneursa to its portfolio

Shionogi announced it will acquire Austin-based biotech IntraBio for $2 billion paid upfront.

The deal brings IntraBio’s oral therapy Aqneursa into Shionogi’s rare‑disease pipeline, expanding its portfolio.

The acquisition reflects Shionogi’s strategy to strengthen its presence in the rare‑disease market as part of its growth plan.